Drug Profile
Dapiglutide - Zealand Pharma
Alternative Names: Dual GLP-1R/GLP-2R agonist - Zealand Pharma; Dual-acting peptide therapeutic - Zealand Pharma; Dual-GLP-1/GLP-2 acting peptide - Zealand Pharma; GLP-1/GLP-2 receptor agonist - Zealand Pharma; ZP-7570Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Class Peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- No development reported Gastrointestinal disorders; Short bowel syndrome
Most Recent Events
- 08 Jan 2024 Zealand Pharma plans a phase IIb trial for Obesity in early 2025
- 28 Nov 2023 No recent reports of development identified for phase-I development in Short-bowel-syndrome(In volunteers, In adults) in Germany (SC, Injection)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in Denmark (SC, Injection)